+357 96 030922
info@marketpublishers.com

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/G388AFA17DEDEN.html
Date: September 2026
Pages: 102
Price: US$ 4,480.00 (Single User License)
ID: G388AFA17DEDEN

Abstracts

The global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market size is expected to reach $ 422 million by 2032, rising at a market growth of 9.3% CAGR during the forecast period (2026-2032).

CD73- and DDR1-targeted drugs for digestive system tumors are therapeutic or diagnostic agents designed to selectively bind to or inhibit CD73 or discoidin domain receptor 1 (DDR1), two proteins involved in tumor growth, immune evasion, stromal remodeling, invasion and treatment resistance in gastrointestinal cancers.

CD73-targeted drugs act against ecto-5?-nucleotidase, an enzyme that converts extracellular AMP into immunosuppressive adenosine. By blocking CD73 or using CD73 as a tumor-associated imaging target, these agents aim to reduce adenosine-mediated immune suppression, improve antitumor immune responses and identify CD73-expressing lesions.

DDR1-targeted drugs act against a collagen-activated receptor tyrosine kinase that regulates tumor–stroma interactions, extracellular-matrix signaling, cancer-cell migration and fibrotic barriers. Inhibiting or targeting DDR1 may reduce tumor invasion, improve immune-cell penetration and enhance drug delivery.

Report Scope

This report studies the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors demand, key companies, and key regions.

+357 96 030922
info@marketpublishers.com

This report is a detailed and comprehensive analysis of the world market for CD73 and DDR1-Targeted Drugs for Digestive System Tumors, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of CD73 and DDR1-Targeted Drugs for Digestive System Tumors that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors total market, 2021-2032, (USD Million)

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors total market, key domestic companies, and share, (USD Million)

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors revenue by player, revenue and market share 2021-2026, (USD Million)

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors total market by Type, CAGR, 2021-2032, (USD Million)

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Arcus Biosciences / Gilead Sciences, AstraZeneca, Akeso, TJ Bio, I-Mab Biopharma, Innate Pharma, Phanes Therapeutics, Incyte Corp, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices

+357 96 030922
info@marketpublishers.com

used in analyzing the world CD73 and DDR1-Targeted Drugs for Digestive System Tumors market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market, Segmentation by Type:

CD73 Target

DDR1 Target

+357 96 030922
info@marketpublishers.com

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market, Segmentation by Nucleoside:

68Ga

18F

Lu177

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market, Segmentation by Indications:

Gastric Cancer

Colorectal Cancer

Pancreatic Cancer

Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market, Segmentation by Application:

Diagnosis

Therapeutics

Companies Profiled:

Arcus Biosciences / Gilead Sciences

AstraZeneca

Akeso

+357 96 030922
info@marketpublishers.com

TJ Bio

I-Mab Biopharma

Innate Pharma

Phanes Therapeutics

Incyte Corp

Key Questions Answered

1. How big is the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
2. What is the demand of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
3. What is the year over year growth of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
4. What is the total value of the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
5. Who are the Major Players in the global CD73 and DDR1-Targeted Drugs for Digestive System Tumors market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Introduction
1.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size & Forecast (2021 & 2025 & 2032)
1.3 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Total Market by Region (by Headquarter Location)
  1.3.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
  1.3.3 China Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
  1.3.4 Europe Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
  1.3.5 Japan Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
  1.3.6 South Korea Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
  1.3.7 ASEAN Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
  1.3.8 India Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value by Region
  2.2.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value by Region (2021-2026)
  2.2.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors

+357 96 030922
info@marketpublishers.com

Consumption Value Forecast by Region (2027-2032)
2.3 United States CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.4 China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.5 Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.6 Japan CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.7 South Korea CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.8 ASEAN CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)
2.9 India CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032)

3 WORLD CD73 AND DDR1-TARGETED DRUGS FOR DIGESTIVE SYSTEM TUMORS COMPANIES COMPETITIVE ANALYSIS

3.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
  3.2.1 Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Industry Rank of Major Players
  3.2.2 Global Concentration Ratios (CR4) for CD73 and DDR1-Targeted Drugs for Digestive System Tumors in 2025
  3.2.3 Global Concentration Ratios (CR8) for CD73 and DDR1-Targeted Drugs for Digestive System Tumors in 2025
3.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Company Evaluation Quadrant
3.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Overall Company Footprint Analysis
  3.4.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Region Footprint
  3.4.2 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Company Product Type Footprint
  3.4.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Company Product Application Footprint
3.5 Competitive Environment

+357 96 030922
info@marketpublishers.com

3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Comparison
4.2.1 United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies and Market Share, 2021-2026
4.3.1 United States Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies, Headquarters (States, Country)
4.3.2 United States Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, (2021-2026)
4.4 China Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue and Market Share, 2021-2026
4.4.1 China Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, (2021-2026)
4.5 Rest of World Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies and Market Share, 2021-2026
4.5.1 Rest of World Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2026)

+357 96 030922
info@marketpublishers.com

5 MARKET ANALYSIS BY TYPE

5.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
  5.2.1 CD73 Target
  5.2.2 DDR1 Target
5.3 Market Segment by Type
  5.3.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2021-2026)
  5.3.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2027-2032)
  5.3.3 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY NUCLEOSIDE

6.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Overview by Nucleoside: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Nucleoside
  6.2.1 68Ga
  6.2.2 18F
  6.2.3 Lu177
6.3 Market Segment by Nucleoside
  6.3.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside (2021-2026)
  6.3.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside (2027-2032)
  6.3.3 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside (2027-2032)

7 MARKET ANALYSIS BY INDICATIONS

7.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Overview by Indications: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Indications
  7.2.1 Gastric Cancer
  7.2.2 Colorectal Cancer
  7.2.3 Pancreatic Cancer

+357 96 030922
info@marketpublishers.com

7.3 Market Segment by Indications
7.3.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications (2021-2026)
7.3.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications (2027-2032)
7.3.3 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Diagnosis
8.2.2 Therapeutics
8.3 Market Segment by Application
8.3.1 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026)
8.3.2 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2027-2032)
8.3.3 World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Arcus Biosciences / Gilead Sciences
9.1.1 Arcus Biosciences / Gilead Sciences Details
9.1.2 Arcus Biosciences / Gilead Sciences Major Business
9.1.3 Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.1.4 Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 Arcus Biosciences / Gilead Sciences Recent Developments/Updates
9.1.6 Arcus Biosciences / Gilead Sciences Competitive Strengths & Weaknesses
9.2 AstraZeneca
9.2.1 AstraZeneca Details
9.2.2 AstraZeneca Major Business
9.2.3 AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services

+357 96 030922
info@marketpublishers.com

9.2.4 AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 AstraZeneca Recent Developments/Updates
9.2.6 AstraZeneca Competitive Strengths & Weaknesses
9.3 Akeso
9.3.1 Akeso Details
9.3.2 Akeso Major Business
9.3.3 Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.3.4 Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Akeso Recent Developments/Updates
9.3.6 Akeso Competitive Strengths & Weaknesses
9.4 TJ Bio
9.4.1 TJ Bio Details
9.4.2 TJ Bio Major Business
9.4.3 TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.4.4 TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 TJ Bio Recent Developments/Updates
9.4.6 TJ Bio Competitive Strengths & Weaknesses
9.5 I-Mab Biopharma
9.5.1 I-Mab Biopharma Details
9.5.2 I-Mab Biopharma Major Business
9.5.3 I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.5.4 I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 I-Mab Biopharma Recent Developments/Updates
9.5.6 I-Mab Biopharma Competitive Strengths & Weaknesses
9.6 Innate Pharma
9.6.1 Innate Pharma Details
9.6.2 Innate Pharma Major Business
9.6.3 Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.6.4 Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Innate Pharma Recent Developments/Updates

+357 96 030922
info@marketpublishers.com

9.6.6 Innate Pharma Competitive Strengths & Weaknesses
9.7 Phanes Therapeutics
9.7.1 Phanes Therapeutics Details
9.7.2 Phanes Therapeutics Major Business
9.7.3 Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.7.4 Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Phanes Therapeutics Recent Developments/Updates
9.7.6 Phanes Therapeutics Competitive Strengths & Weaknesses
9.8 Incyte Corp
9.8.1 Incyte Corp Details
9.8.2 Incyte Corp Major Business
9.8.3 Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
9.8.4 Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Incyte Corp Recent Developments/Updates
9.8.6 Incyte Corp Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Industry Chain
10.2 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Upstream Analysis
10.3 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Midstream Analysis
10.4 CD73 and DDR1-Targeted Drugs for Digestive System Tumors Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key CD73 and DDR1-Targeted Drugs for Digestive System Tumors Players in 2025
Table 12. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Company Evaluation Quadrant
Table 14. Head Office of Key CD73 and DDR1-Targeted Drugs for Digestive System Tumors Players
Table 15. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Company Product Type Footprint
Table 16. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market: Company Product Application Footprint
Table 17. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Mergers & Acquisitions Activity
Table 18. United States VS China CD73 and DDR1-Targeted Drugs for Digestive

+357 96 030922
info@marketpublishers.com

System Tumors Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies, Headquarters (States, Country)
Table 21. United States Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share (2021-2026)
Table 23. China Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies, Headquarters (Province, Country)
Table 24. China Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share (2021-2026)
Table 26. Rest of World Based CD73 and DDR1-Targeted Drugs for Digestive System Tumors Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share (2021-2026)
Table 29. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type (2027-2032) & (USD Million)
Table 32. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside, (USD Million), 2021 & 2025 & 2032
Table 33. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Value by Nucleoside (2021-2026) & (USD Million)
Table 34. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside (2027-2032) & (USD Million)
Table 35. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications, (USD Million), 2021 & 2025 & 2032
Table 36. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Value by Indications (2021-2026) & (USD Million)
Table 37. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market

+357 96 030922
info@marketpublishers.com

Size by Indications (2027-2032) & (USD Million)
Table 38. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2021-2026) & (USD Million)
Table 40. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application (2027-2032) & (USD Million)
Table 41. Arcus Biosciences / Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 42. Arcus Biosciences / Gilead Sciences Major Business
Table 43. Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 44. Arcus Biosciences / Gilead Sciences CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Arcus Biosciences / Gilead Sciences Recent Developments/Updates
Table 46. Arcus Biosciences / Gilead Sciences Competitive Strengths & Weaknesses
Table 47. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 48. AstraZeneca Major Business
Table 49. AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 50. AstraZeneca CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. AstraZeneca Recent Developments/Updates
Table 52. AstraZeneca Competitive Strengths & Weaknesses
Table 53. Akeso Basic Information, Manufacturing Base and Competitors
Table 54. Akeso Major Business
Table 55. Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 56. Akeso CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Akeso Recent Developments/Updates
Table 58. Akeso Competitive Strengths & Weaknesses
Table 59. TJ Bio Basic Information, Manufacturing Base and Competitors
Table 60. TJ Bio Major Business
Table 61. TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 62. TJ Bio CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 63. TJ Bio Recent Developments/Updates
Table 64. TJ Bio Competitive Strengths & Weaknesses
Table 65. I-Mab Biopharma Basic Information, Manufacturing Base and Competitors
Table 66. I-Mab Biopharma Major Business
Table 67. I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 68. I-Mab Biopharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. I-Mab Biopharma Recent Developments/Updates
Table 70. I-Mab Biopharma Competitive Strengths & Weaknesses
Table 71. Innate Pharma Basic Information, Manufacturing Base and Competitors
Table 72. Innate Pharma Major Business
Table 73. Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 74. Innate Pharma CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Innate Pharma Recent Developments/Updates
Table 76. Innate Pharma Competitive Strengths & Weaknesses
Table 77. Phanes Therapeutics Basic Information, Manufacturing Base and Competitors
Table 78. Phanes Therapeutics Major Business
Table 79. Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 80. Phanes Therapeutics CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Phanes Therapeutics Recent Developments/Updates
Table 82. Phanes Therapeutics Competitive Strengths & Weaknesses
Table 83. Incyte Corp Basic Information, Manufacturing Base and Competitors
Table 84. Incyte Corp Major Business
Table 85. Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Product and Services
Table 86. Incyte Corp CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Incyte Corp Recent Developments/Updates
Table 88. Incyte Corp Competitive Strengths & Weaknesses
Table 89. Global Key Players of CD73 and DDR1-Targeted Drugs for Digestive System Tumors Upstream (Raw Materials)
Table 90. Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Picture
Figure 2. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Total Revenue (2021-2032) & (USD Million)
Figure 4. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue (2021-2032) & (USD Million)
Figure 13. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 16. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Market Share by Region (2021-2032)
Figure 17. United States CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 18. China CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe CD73 and DDR1-Targeted Drugs for Digestive System Tumors

+357 96 030922
info@marketpublishers.com

Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 23. India CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of CD73 and DDR1-Targeted Drugs for Digestive System Tumors by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for CD73 and DDR1-Targeted Drugs for Digestive System Tumors Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for CD73 and DDR1-Targeted Drugs for Digestive System Tumors Markets in 2025
Figure 27. United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: CD73 and DDR1-Targeted Drugs for Digestive System Tumors Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type in 2025
Figure 31. CD73 Target
Figure 32. DDR1 Target
Figure 33. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Type (2021-2032)
Figure 34. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Nucleoside, (USD Million), 2021 & 2025 & 2032
Figure 35. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside in 2025
Figure 36. 68Ga
Figure 37. 18F
Figure 38. Lu177
Figure 39. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Nucleoside (2021-2032)
Figure 40. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Indications, (USD Million), 2021 & 2025 & 2032
Figure 41. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market

+357 96 030922
info@marketpublishers.com

Size Market Share by Indications in 2025
Figure 42. Gastric Cancer
Figure 43. Colorectal Cancer
Figure 44. Pancreatic Cancer
Figure 45. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Indications (2021-2032)
Figure 46. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 47. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application in 2025
Figure 48. Diagnosis
Figure 49. Therapeutics
Figure 50. World CD73 and DDR1-Targeted Drugs for Digestive System Tumors Market Size Market Share by Application (2021-2032)
Figure 51. CD73 and DDR1-Targeted Drugs for Digestive System Tumors Industrial Chain
Figure 52. Methodology
Figure 53. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global CD73 and DDR1-Targeted Drugs for Digestive System Tumors Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/G388AFA17DEDEN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G388AFA17DEDEN.html